Rankings
▼
Calendar
IONS Q3 2023 Earnings — Ionis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
IONS
Ionis Pharmaceuticals, Inc.
$13B
Q3 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$144M
-9.7% YoY
Gross Profit
$142M
98.5% margin
Operating Income
-$143M
-99.3% margin
Net Income
-$147M
-102.2% margin
EPS (Diluted)
$-1.03
QoQ Revenue Growth
-23.5%
Cash Flow
Operating Cash Flow
-$109M
Free Cash Flow
-$112M
Stock-Based Comp.
$26M
Balance Sheet
Total Assets
$2.9B
Total Liabilities
$2.6B
Stockholders' Equity
$315M
Cash & Equivalents
$352M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$144M
$160M
-9.7%
Gross Profit
$142M
$158M
-10.3%
Operating Income
-$143M
-$59M
-142.2%
Net Income
-$147M
-$47M
-213.7%
Revenue Segments
Commercial
$84M
28%
SPINRAZA Royalties
$67M
22%
Research and Development Revenue
$60M
20%
Collaborative Agreement Revenue
$44M
14%
Other Commercial
$17M
6%
Eplontersen Joint Development Revenue
$16M
5%
Licensing and Other Royalties
$9M
3%
Product
$8M
3%
← FY 2023
All Quarters
Q4 2023 →